Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer Names New Chief Scientific Officer For Neuroscience Unit
Mr Ehlers most recently served as the George Barth Geller professor in the department of neurobiology at Duke University and as an investigator with the Howard Hughes Medical
Mr Ehlers most recently served as the George Barth Geller professor in the department of neurobiology at Duke University and as an investigator with the Howard Hughes Medical
Discovery Labs claimed that if approved, Surfaxin would be the first synthetic, peptide-containing surfactant for commercial use in neonatal medicine. Discovery Labs plans to submit its complete response
California-based Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Xpert
Orexins are neuropeptides (chemical messengers) that are released by specialised neurons in the hypothalamus region of the brain and are believed to be an important regulator of the
Sysmex America was also awarded a three-year sole-source hematology agreement for Premier’s Accelerated Supply Chain Endeavor (ASCEND) program member-participants. ASCEND helps Premier members achieve sustained improvement in supply
Novacta Biosystems, a UK-based biotechnology company controlled by Celtic Pharma, is focused on bringing new and modern anti infective therapies to the market. DSM it has completed the
The issued patent generally claims methods of enhancing the RNA silencing activity of RNA interference (RNAi) agents through certain structural modifications. The issued claims not only cover enhancing
Thiopurine drugs suppress the immune system and are used in the treatment of a wide range of diseases, such as inflammatory bowel disease, leukemia and lymphoma, autoimmune diseases
Astellas has completed the acquisition of OSI through a short-form merger without a meeting of OSI’s stockholders. In the merger, each outstanding share of OSI common stock not
Absorption Systems said that the services offer enhanced value across three critical elements: robust assay designs, timely project execution and data interpretation focused on the advancement potential of